SureTrader
Home > Boards > US Listed > Biotechs > Peregrine Pharmaceuticals (PPHM)

ATM Sales Summary (3-2009 thru 6-30-2012)…

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
cjgaddy Member Profile
 
Followed By 62
Posts 4,714
Boards Moderated 1
Alias Born 01/24/04
160x600 placeholder
Avid Bioservices to Participate in Cambridge Healthtech Institute’s (CHI) 8th Annual The Bioprocessing Summit "GlobeNewswire Inc." - 8/9/2016 8:05:00 AM
Peregrine Pharmaceuticals Reports Financial Results for Quarter and Fiscal Year Ended April 30, 2016 and Recent Developments "GlobeNewswire Inc." - 7/14/2016 4:05:00 PM
Peregrine Licenses Novel Exosome-Based Cancer Detection and Monitoring Technology from UT Southwestern Medical Center "GlobeNewswire Inc." - 7/14/2016 8:05:00 AM
Peregrine to Report Financial Results for the Quarter and Fiscal Year Ended April 30, 2016 After Market Close on July 14, 201... "GlobeNewswire Inc." - 7/7/2016 4:05:00 PM
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock "GlobeNewswire Inc." - 6/2/2016 4:00:00 PM
Peregrine Pharmaceuticals Provides Corporate Update Highlighting Latest Developments for Contract Manufacturing and Drug Deve... "GlobeNewswire Inc." - 6/2/2016 8:05:00 AM
Preclinical Data Presented at American Association for Cancer Research (AACR) Annual Meeting Demonstrate Enhanced Therapeutic... "GlobeNewswire Inc." - 4/20/2016 8:05:00 AM
Form 8-K - Current report "Edgar (US Regulatory)" - 4/12/2016 4:31:41 PM
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock "GlobeNewswire Inc." - 3/9/2016 7:46:45 PM
Peregrine Pharmaceuticals Announces Formal Commissioning of New, State-of-the-Art Commercial Manufacturing Facility "GlobeNewswire Inc." - 3/9/2016 7:46:43 PM
Peregrine to Report Financial Results for Third Quarter of Fiscal Year 2016 Prior to Market Open on March 9, 2016 "GlobeNewswire Inc." - 3/9/2016 7:46:38 PM
Peregrine Pharmaceuticals Provides Update on Phase III SUNRISE Trial of Bavituximab "GlobeNewswire Inc." - 3/9/2016 7:46:14 PM
Peregrine Pharmaceuticals Reports Financial Results for Third Quarter of Fiscal Year 2016 and Recent Developments "GlobeNewswire Inc." - 3/9/2016 8:00:00 AM
Peregrine Alert -- National Securities Law Firm Continues Investigation of Peregrine Pharmaceuticals, Inc. for Potential Secu... "PR Newswire (US)" - 2/29/2016 9:30:00 AM
Peregrine Alert -- National Securities Law Firm Investigates Peregrine Pharmaceuticals, Inc. for Potential Securities Law Cla... "PR Newswire (US)" - 2/26/2016 3:09:00 PM
Four Biotech Small Caps with Near Term Catalysts to Keep on Your Radar "InvestorsHub NewsWire" - 1/27/2016 8:00:00 AM
Peregrine Pharmaceuticals to Present at Two Upcoming Cancer Immunotherapy Conferences "GlobeNewswire Inc." - 1/20/2016 8:05:00 AM
Peregrine Pharmaceuticals Provides Update on Planned Expansion of Bavituximab Clinical Program in Lung, Breast and Other Canc... "GlobeNewswire Inc." - 1/11/2016 8:05:00 AM
Peregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration to Evaluate Novel Canc... "GlobeNewswire Inc." - 1/6/2016 8:05:00 AM
Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2016 and Recent Developments "GlobeNewswire Inc." - 12/10/2015 4:05:00 PM
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock "GlobeNewswire Inc." - 12/7/2015 4:05:00 PM
It's the Little Things That Matter for Peregrine Pharmaceuticals "The Motley Fool" - 12/4/2015 10:46:03 AM
Peregrine to Report Financial Results for Second Quarter of Fiscal Year 2016 After Market Close on December 10, 2015 "GlobeNewswire Inc." - 12/3/2015 4:05:00 PM
Peregrine Pharmaceuticals to Participate in Two Upcoming Life Science Investor Conferences "GlobeNewswire Inc." - 11/23/2015 8:05:00 AM
Feature Analyst Alert and 4 Brief Updates "InvestorsHub NewsWire" - 11/10/2015 8:00:00 AM
cjgaddy   Saturday, 07/21/12 11:34:42 AM
Re: cjgaddy post# 84279
Post # of 271207 
ATM Sales Summary (3-2009 thru 6-30-2012)…

ATM = “At-The-Market Sales Issuance”

I. WM-SMITH:
• $7.5mm ATM/Wm.SMITH 3-26-09: $7,500,000gr. / 2,150,759sh. = $3.49/sh. (commiss: 3%)
• $25mm ATM/Wm.SMITH 7-14-09: $25,000,000gr. / 7,569,314sh. = $3.30/sh. (commiss: 3%/1st$15mm, then 2%)
*Total Raised via WmSmith ATM Sales thru 7-31-10:
. . . . $32,500,000gr. / 9,720,073sh. = $3.34/sh.

II. MLV 6-2010: http://www.mlvco.com
$15mm ATM/MLV 6-22-10 (commiss: 2%) Form424: http://tinyurl.com/24txkxb
• Sold 6/22/10–10/31/10: $6,840,000gr. / 4,031,018sh. = $1.70/sh.
• Sold 11/1/10–11/30/10: $7,407,000gr. / 4,711,611sh. = $1.57/sh.
• Sold 12/1/10–1/31/11: $753,000gr. / 471,744sh. = $1.60/sh.
*Total Raised via MLV June’10 ATM Sales thru 1-31-11:
. . . . $15,000,000gr. / 9,214,373 = $1.63/sh.

III. MLV 12-2010: “Dec’10 AMI Agreement” http://www.mlvco.com
$75mm ATM/MLV 12-29-10 (commiss: max=5%) Form8K: http://tinyurl.com/2a6w76g
(pursuant to $75mm S-3 Shelf Reg. filed 12-17-10: http://tinyurl.com/2469b2d )
• Sold 12/29/10-1/31/11: $6,460,000gr. / 2,385,862sh. = $2.71/sh.
• Sold 2/1/11-2/28/11: $2,358,000gr. / 998,142sh. = $2.36/sh.
• Sold 3/1/11-4/30/11: $4,470,000gr. / 1,840,487sh. = $2.43/sh.
• Sold 5/1/11-7/31/11: $3,713,000gr. / 1,912,576sh. = $1.94/sh.
• Sold 8/1/11-10/31/11: $5,582,000gr. / 4,727,840sh. = $1.18/sh.
• Sold 11/1/11-1/31/12: $10,961,000gr. / 10,308,025sh. = $1.06/sh.
• Sold 2/1/12-2/29/12: $5,871,000gr. / 5,726,946sh. = $1.03/sh.
• Sold 3/1/12-4/30/12: $1,263,000gr. / 2,198,543sh. = $.57/sh.
• Sold 5/1/12-6/30/12: $1,496,000gr. / 2,752,691sh. = $.54/sh.
*Total Raised via MLV Dec’10 ATM Sales thru 6-30-2012:
. . . . $42,174,000gr. / 32,851,112 = $1.28sh.

TOTAL ALL A-T-M SALES – INCEPTION (3-2009) THRU 6-30-2012:
==> $89,674,000gr. / 51,785,558sh. = $1.73/sh.

- - - - - - - - - -
10-31-11 10Q: “During the 6mos. 10-31-11, we sold 6,440,416 shares of our common stock at mkt-prices for gross proceeds of $9,295,000 under the Dec’10 AMI Agreement before deducting commissions and other issuance costs of $260,000”
1-31-12 10Q: “During the 9mos. ended 1-31-12, we sold 16,948,441 shares of our common stock at mkt-prices for gross proceeds of $20,256,000 under the Dec’10 AMI Agreement before deducting commissions and other issuance costs of $482,000. …During Feb.2012, we sold an addl. 5,726,946 shares of common stock at market prices under the Dec’10 AMI Agreement in exchange for aggregate gross proceeds of $5,871,000. As of 2-29-12, gross proceeds of $38,644,000 remained available under our 2 effective shelf registration statements.”
4-30-12 10K: “Under the Dec. 2010 AMI Agreement with MLV …for aggregate gross proceeds of up to $75,000,000… During FY’s 2011 (5’10-4’11) and 2012 (5’11-4’12), we sold 30,098,421 shares of common stock at market prices under the Dec.2010 AMI for aggregate gross proceeds of $40,678,000 before deducting commissions & other issuance costs of $917,000. As of April 30, 2012, aggregate gross proceeds of up to $27,382,000 remained available under the Dec.2010 AMI… Subsequent to April 30, 2012 and through June 30, 2012, we sold 2,752,691 shares of common stock at mkt prices under the Dec.2010 AMI for aggregate gross proceeds of $1,496,000.

ALL SEC filings for PPHM: http://tinyurl.com/6d4jw8

Shelf-Date Registration# Amt-Registered
• Jan2007 #333-139975 $30,000,000
• July2009 #333-160572 $50,000,000
• Dec2010 #333-171252 $75,000,000
• Mar9-2012 “PPHM files shelf to sell up to $150mm common stock, warrants”, S3: http://tinyurl.com/7dl7pjm - CFO Paul Lytle, 3-9-12/CC: ”In closing, let me say that we are planning for success as we get closer to unblinding data from our 2nd-line NSCLC study and reporting several other clinical data points from our other ongoing trials. And it's important to note that while we always seek other non-dilutive opportunities to fund our future development efforts, it is always prudent to prepare for other ways to fund our operations. In line with this strategy, we will be filing a new shelf-registration statement later today as a potential measure to assist us at advancing our pipeline of novel drug candidates. We look forward to keeping you updated on our progress. . .” PL/Q&A: “And our goal is really to plan for success here and having an effective shelf in place allows us to plan for success. Obviously, our goal is to look at potential partnerships as we move forward to help fund these bigger Phase III studies that we're anticipating based on promising data. But we want to be prepared internally to have an additional vehicle in place; assuming you can't determine when and the time frame of a potential partnership. So we just want to make sure we're taking prudent measures internally to prepare ourselves for success, and in a shelf that will last 3 years, once it’s declared effective. ”
• CFO Paul Lytle, 7-16-12/CC: ”In addition to our focus on growing Avid revenues, our next immediate focus is to secure a less-dilutive debt-financing vehicle, similar to a term loan. Recognizing the growing value in the Avid asset, and the strong clinical data in 2nd-Line NSCLC, we are pursuing a non-convertible-type loan in the range of $20-30mm. We will keep you updated as we get closer to a possible transaction.” ( http://tinyurl.com/cs7spbz )

SureTrader
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist